pI: 6.4884 |
Length (AA): 264 |
MW (Da): 28524 |
Paralog Number:
5
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 4 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
1 | 251 | 2b81 (A) | 16 | 302 | 24.00 | 0 | 1 | 1.10976 | 0.12 |
11 | 129 | 6fri (A) | 1 | 123 | 19.00 | 0 | 0.83 | 0.637758 | -0.33 |
11 | 255 | 1f07 (A) | 1 | 217 | 28.00 | 0.00000014 | 1 | 1.16823 | 0.13 |
30 | 137 | 3sdo (A) | 40 | 155 | 34.00 | 0.03 | 1 | 0.670291 | 0.02 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Dormant phase. | hasan |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Dormant phase. | murphy |
murphy | Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. |
hasan | Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. |
Ortholog group members (OG5_146706)
Species | Accession | Gene Product |
---|---|---|
Mycobacterium tuberculosis | Rv2161c | Conserved protein |
Mycobacterium tuberculosis | Rv0132c | Putative F420-dependent glucose-6-phosphate dehydrogenase Fgd2 |
Mycobacterium tuberculosis | Rv0044c | Possible oxidoreductase |
Mycobacterium tuberculosis | Rv3079c | Conserved protein |
Mycobacterium tuberculosis | Rv1855c | Possible oxidoreductase |
Mycobacterium tuberculosis | Rv0953c | Possible oxidoreductase |
Mycobacterium ulcerans | MUL_2862 | oxidoreductase |
Mycobacterium ulcerans | MUL_2792 | hypothetical protein |
Mycobacterium ulcerans | MUL_2498 | hypothetical protein |
Mycobacterium ulcerans | MUL_0292 | hypothetical protein |
Mycobacterium ulcerans | MUL_1043 | hypothetical protein |
Mycobacterium ulcerans | MUL_3024 | oxidoreductase |
Mycobacterium ulcerans | MUL_0062 | oxidoreductase |
Mycobacterium ulcerans | MUL_3991 | flavin-dependent oxidoreductase |
Mycobacterium ulcerans | MUL_5034 | hypothetical protein |
Mycobacterium ulcerans | MUL_3458 | oxidoreductase |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
mtu133 | Mycobacterium tuberculosis | non-essential | nmpdr |
mtu44 this record | Mycobacterium tuberculosis | non-essential | nmpdr |
mtu968 | Mycobacterium tuberculosis | non-essential | nmpdr |
mtu2195 | Mycobacterium tuberculosis | non-essential | nmpdr |
mtu3132 | Mycobacterium tuberculosis | non-essential | nmpdr |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.